Yeast Infections
Also known as: Candidiasis, Moniliasis
Methodology & AI Transparency ⓘ
Yeast Infections Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Candida is the scientific name for yeast.
- 2 Real-world patient consensus: Mapped to Bacterial, Viral & Fungal Infections under ICD-10-CM B37.9 for Yeast Infections clinical workups.
- 3 Typical cash cost range: Differential triage of Yeast Infections (B37.9) utilizes antimicrobial stewardship (narrow-spectrum in Yeast Infections (B37.9: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Longitudinal Yeast Infections monitoring tracks Complete Blood Count in Yeast Infections (B37.9: (WBC & Differential)) toward WBC 4.0 – 10.0 x10^3/uL (B37.9).
Ask our AI Specialists anything about Yeast Infections
What Is Yeast Infections?
Candida is the scientific name for yeast. It is a fungus that lives almost everywhere, including in your body. Usually, your immune system keeps yeast under control. If you are sick or taking antibiotics, it can multiply and cause an infection. Yeast infections affect different parts of the body in different ways: Thrush is a yeast infection that causes white patches in your mouth Candida esophagitis is thrush that spreads to your esophagus, the tube that takes food from your mouth to your stomach. It can make it hard or painful to swallow.
Pathophysiology, Underlying Causes & Clinical Presentation
In Yeast Infections (B37.9), physiological disruption stems from or fungal) epithelial in Yeast Infections (B37.9: invasion), Cross-referenced with NIH MeSH (Candidiasis), informing Bacterial, Viral & Fungal Infections protocols that track C-Reactive Protein / in Yeast Infections (B37.9: Procalcitonin) (Resolution to baseline (B37.9)).
Common Symptoms & Clinical Signs
- • Thrush is a yeast infection that causes white patches in your mouth
- • Women can get vaginal yeast infections, causing vaginitis
- • Presentation of Yeast Infections (B37.9): painful vesicular rash in Yeast Infections (B37.9: in a dermatomal)
- • Secondary Yeast Infections clinical sign: regional lymph node in Yeast Infections (B37.9: tenderness or acute)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Yeast Infections Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B37.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Yeast Infections (B37.9: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B37.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Yeast Infections (B37.9: Procalcitonin) | Resolution to baseline (B37.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Yeast Infections (B37.9: Culture & Sensitivity) | Pathogen clearance / negative test (B37.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Yeast Infections
Treatment selection for Yeast Infections depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Yeast Infections)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Safety and real-world benefits of a single dose of oral azithromycin given in There was a modest relative reduction in infant SSTIs but this was small in absolute terms with no statistically discernible difference. BMC medicine • 2025-04-28 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40289086 ↗ |
| Can This Approach Help? Inside the Latest Research on Population how the body absorbs the medicine Evaluation of Amikacin Liposome Systemic exposure to amikacin in serum and urine following once-daily ALIS administration in patients with treatment-refractory NTM lung disease was notably lower than that previously reported for parenteral amikacin. European journal of drug metabolism and pharmacokinetics • 2021-03-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33595792 ↗ |
Yeast Infections Patient Community & “People Like Me” Threads
Filter Yeast Infections community threads and patient logs by age, biological sex, dosage, and treatment duration.